Laddar populära aktier...
Slutliga data från fas 2b-studien Top-line data från fas 2b-studien mot degenerativ disksjukdom uppn...
2nd quarter in a row with q-o-q sales growth Freshness unit is driving the recovery Same story in th...
See what other investors are asking and the answers from Redeye's dedicated analyst in the latest An...
Med förväntningar om produktionsstart under 2024 och goda möjligheter för positiva nyheter när den n...
Neutral Q4’23 rapport Midsummer rapporterade en i våra ögon relativt neutral rapport.
Stark onlinetillväxt kompenserar för fortsatt utsatt distributionskanal Björn Borgs omsättning för Q...
Ingen vändning i NAV-utveckling NAV efter kvartalets utgång uppgick till 281 kr, vilket motsvarar en...
Redeye shares its initial view on Xbrane's year-end report, which was higher than anticiated on reve...
Scanfil’s performance remained strong in Q4 and was largely as expected.
The acting CEO Teemu Tunkelo will leave his position immediately according to a press release this m...
Adjusted earnings in line, strong cash flow Financial risk has come down notably EBITA down 2% for '...
Redeye provides a research update on Smart Eye following the Q4 2023 report.
Redeye provides an update in relation to CLS’ Q4 2023 report.
Redeye alters the medium-term growth outlook on the back of a very upbeat CMD held by Tobii Dynavox ...